Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Leerink Partners downgraded Johnson & Johnson (NYSE:JNJ) and Halozyme Therapeutics (NASDAQ:HALO) on Tuesday, indicating a faster-than-expected timeline for the companies’ combination drug products to ...

Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

Leerink Partnrs also issued estimates for Acadia Healthcare’s Q3 2025 earnings at $0.78 EPS, Q4 2025 earnings at $0.79 EPS, Q1 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.72 EPS, Q3 2026 ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (LSE:0J2O) from Market Perform to Underperform. As of May 7, 2025, the average one-year ...

After A Q4 Miss, LifePoint Health Downgraded By Leerink On Free Cash Flow Concerns Leerink: Bluebird Bio's Catalysts Are Priced In Plenty Of Opportunity In AbbVie, Even After Recent Run Leerink ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Kymera Therapeutics (KYMR – Research Report) on April 22. The company’s shares closed yesterday at $30.70. Discover ...

Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings per share of $5.20 for the year, down from their previous […] Skip to main content Analyst Ratings ...

Leerink Partners downgraded Johnson & Johnson (NYSE:JNJ) and Halozyme Therapeutics (NASDAQ:HALO) on Tuesday, indicating a faster-than-expected timeline for the companies’ combination drug ...